LGD-4033/YK-11

• LGD-4033: 50 mg/mL
• YK-11: 50 mg/mL

LGD-4033/YK-11 is evaluated as a combined formulation rather than a single active compound. Each component contributes to research-relevant biochemical pathways: The combined formulation is commonly explored in studies evaluating potential additive or synergistic effects on lean-mass-related endpoints, strength proxies, and recovery variables. Mechanistic attribution generally requires structured comparator groups using the individual compounds.

• LGD-4033 (Ligandrol): Studied as a selective androgen receptor modulator (SARM), commonly investigated for its ability to selectively activate androgen receptor signaling in target tissues under controlled laboratory conditions
• YK-11: Investigated in muscle-cell research for its association with myostatin-related signaling pathways and downstream differentiation markers, often discussed as a myostatin-linked anabolic variable

LGD-4033/YK-11 is commonly studied in

• Androgen receptor signaling and anabolic-transcription research
• Muscle-hypertrophy and myogenic-differentiation models
• Myostatin-related pathway investigations and downstream anabolic biomarkers
• Strength and performance proxy endpoints in controlled nonclinical studies
• Body-composition research in which dietary intake and training variables are standardized

Reported observations are model- and dose-dependent and may include

• Suppression-like findings in endogenous gonadal-axis biomarkers during androgen receptor activation
• Alterations in lipid-related biomarkers in certain experimental settings
• Elevations in liver-enzyme measurements reported in some models and case literature involving related compound classes, warranting appropriate monitoring in research designs
• Androgenic-like findings in models sensitive to androgen receptor activation, including changes in sebaceous-activity biomarkers or behavioral endpoints depending on species and experimental design
• Confounded outcomes when combined with additional androgenic compounds or other anabolic-signaling interventions

LGD-4033/YK-11 is often explored alongside interventions that overlap with its primary mechanistic pathways.